SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell CarcinomaUnusual Whales·Jul 17 at 07:27 AM688506-2.93%02615
China’s Biokin Soars After Its First-in-Class Cancer Drug Is Greenlit for Chinese Market LaunchYicai·Jun 23 at 01:26 AM688506-2.93%BMY+0.69%
15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in Chinaprnewswire·Jun 22 at 02:09 PM688506-2.93%02615
Innovative drug concept repeatedly active, ALK straight to the daily limit, Rundu Pharma previously sealed the board, InventisBio, Junshi Biosciences, HWPC, and Biokin Pharmaceutical rose more than 6%Wallstreetcn·Mar 31 at 09:07 PM159892+0.42%516820+0.58%
Highest 1-Year OS Rate! iza-bren Combined with Sintilimab Achieves 8.2 Months mPFS and 85.7% 1-Year OS Rate in First-Line Extensive-Stage Small Cell Lung CancerWallstreetcn·Mar 25 at 08:41 PM688506-2.93%
Bristol-Myers Squibb Cancer Advances Test Valuation Gap For InvestorsSimplywall·Feb 28 at 06:21 PMPILL-7.82%IHE-0.82%
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancerbiopharmadive·Feb 26 at 07:55 PM688506-2.93%02615
AI Chocolate Development: Barry Callebaut Establishes Global Innovation Center Locally | Lianhe ZaobaoZaobao·Feb 10 at 03:42 AM688506-2.93%
Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%Wallstreetcn·Dec 7, 2025 at 04:48 AM02615688506-2.93%
News: Biokin Pharmaceutical launches Hong Kong IPO and is expected to be included in the Stock ConnectBambooWorks·Nov 7, 2025 at 01:40 AM688506-2.93%
Year-on-year increase of 1625.08%, Biokin Pharmaceutical confirms milestone revenue of 250 million USD in Q3Wallstreetcn·Oct 26, 2025 at 06:13 AM688506-2.93%
Biokin Pharmaceutical released its performance for the first three quarters, with a net loss attributable to the parent company of 495 million yuanZhitong·Oct 26, 2025 at 03:06 AM688506-2.93%
Biokin Pharmaceutical: Clinical trial for injectable BL-M24D1 (ADC) drug approvedZhitong·Oct 21, 2025 at 09:54 AM688506-2.93%
